Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfume trial of binimetinib in BRAF fusion-positive low-grade glioma or pancreatic cancer
jRCT2031230007Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of binimetinib in glioma and pancreatic cancer (PC) (2 cohorts), sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate. Started Mar 2023; status: recruiting.
02
Drugs
binimetinib
03
Conditions
gliomapancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031230007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230007.